InVivo Therapeutics Announces Oral Platform Presentation at 2017 Congress of Neurological Surgeons Annual Meeting
October 10 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced that Stuart Lee, M.D., Investigator at Vidant Medical
Center in Greenville, North Carolina, will be giving an oral
platform presentation titled “Histopathology of Necrotic Spinal
Cord Tissue Exudate Collected During Surgical Implantation of a
Biodegradable Scaffold Following Acute Spinal Cord Injury:
Pre-clinical and Clinical Findings” at the 2017 Congress of
Neurological Surgeons (CNS) Annual Meeting to be held October 7-11,
2017 in Boston, MA. The presentation will be made on Wednesday,
October 11, during the Rapid-Exchange Oral Presentations, Session
2.
Dr. Lee said, “The INSPIRE trial has allowed us to gain new
insights into acute spinal cord injury pathology. I look forward to
sharing these preliminary findings and continuing to explore
INSPIRE data.”
“We look forward to interacting with the neurosurgical community
attending this important conference, and sharing results from the
INSPIRE study that provide new information about the acute phase of
spinal cord injury,” Mark Perrin, Chief Executive Officer and
Chairman, said.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with
proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P.
Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the
company earned the David S. Apple Award from the American Spinal
Injury Association for its outstanding contribution to spinal cord
injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold™ received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171010005454/en/
InVivo Therapeutics Holdings Corp.Heather Hamel,
617-863-5530Investor
RelationsInvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024